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ABSTRACT
Lysophosphatidic acid (LPA) is a bioactive lipid promoting cancer metastasis. 
LPA activates a series of six G protein-coupled receptors (LPA
1-6
). While blockage 
of LPA
1
 in vivo inhibits breast carcinoma metastasis, down-stream genes mediating 
/3$LQGXFHGPHWDVWDVLVKDYHQRWEHHQ\HWLGHQWL¿HG+HUHLQZHVKRZHGE\DQDO\]LQJ
publicly available expression data from 1488 human primary breast tumors that the 
gene encoding the transcription factor ZEB1 was the most correlated with LPAR1 
encoding LPA
1
. This correlation was most prominent in basal primary breast carcinomas 
and restricted to cell lines of basal subtypes. Functional experiments in three different 
basal cell lines revealed that LPA-induced ZEB1 expression was regulated by the 
LPA
1
/Phosphatidylinositol-3-Kinase (Pi3K) axis. DNA microarray and real-time PCR 
analyses further demonstrated that LPA up-regulated the oncomiR miR-21 through an 
LPA
1
/Pi3K/ZEB1-dependent mechanism. Strikingly, treatment with a mirVana miR-
21 inhibitor, or silencing LPA
1
 or ZEB1 completely blocked LPA-induced cell migration 
in vitro, invasion and tumor cell bone colonization in vivo, which can be restored 
with a mirVana miR-21 mimic. Finally, high LPAR1 expression in basal breast tumors 
predicted worse lung-metastasis-free survival. Collectively, our results elucidate a new 
molecular pathway driving LPA-induced metastasis, thus underscoring the therapeutic 
potential of targeting LPA
1
 in patients with basal breast carcinomas.
INTRODUCTION
Lysophosphatidic acid (LPA) is a naturally occurring 
bioactive lipid promoting cancer progression and metastasis 
[1, 2]. LPA exhibits growth-factor-like activities by 
mobilizing multiple intracellular signaling pathways 
down-stream a series of six G protein-coupled receptors 
(LPA
16
) that mediate proliferation, motility, and survival 
of both normal and cancer cells [1, 2]. Pharmacological 
blockage of LPA receptors with the pan-LPA antagonist 
BrP-LPA inhibits human breast MDA-MB-231 cancer cell 
motility in vitro and promotes tumor regression associated 
with a decrease in blood vessel density surrounding the 
tumors in a mouse xenograft model, suggesting that LPA 
signaling may be a potential therapeutic target for patients 
with breast cancers [3]. Among the LPA receptors, LPA
1
 
is up regulated in many types of primary tumors, and 
plays an important role in regulating cancer malignancy 
due to pro-oncogenic and pro-metastatic properties [4]. 
Studies showed that induction of LPA
1
 expression induces 
metastasis in breast and ovarian cancer cells [5, 6] and 
stimulates in the motility of human pancreatic cancer cells 
[7]. Using immune compromised mice we demonstrated 
that expression of this receptor confers a high propensity 
to human breast cancer cells to induce bone metastasis [8]. 
Stable knockdown of LPA
1
 expression (using small-hairpin 
RNAs or treatments with the LPA
13
 antagonist Ki16425) 
inhibited the progression of osteolytic bone metastases 
by impairing breast cancer cell proliferation, motility and 
cytokine secretions [8]. Pharmacological inhibition of 
LPA
1
 with Debio-0719 inhibits spontaneous metastatic 
dissemination of breast cancer cells independently of 
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primary tumor proliferation and angiogenesis [9]. In a later 
stage of cancer progression Debio-0719 induces breast 
metastasis dormancy in a murine model [10]. Therefore, 
LPA
1
 is an attractive target. However the underlying 
mechanism and the genes involved in LPA
1
-mediated breast 
cancer metastatic dissemination remains to be determined.
%UHDVW FDUFLQRPDV DUH FXUUHQWO\ FODVVL¿HG LQ IRXU
molecular subtypes (luminal A, luminal B, HER2-enriched, 
basal-like) based on gene expression patterns [11]. The 
basal-type subgroup also refers as triple negative breast 
cancers (TNBC). Kennecke and colleagues in their seminal 
work determined that TNBC metastasize predominantly 
to the brain and lungs [12]. TNBC constitute 10%-20% of 
all breast cancers [13] and 70% of women with metastatic 
TNBC have a survival rate of less than 5 years [14]. Absence 
of estrogen receptor, progesterone receptor, and HER2/neu 
makes TNBC insensitive to some of the most effective 
therapies available for breast cancer treatment including 
HER2-directed therapy and endocrine therapies urging the 
QHHGIRULGHQWL¿FDWLRQRIQHZPROHFXODUWDUJHWVLQ71%&
In this study we investigated the activated genes 
involved in LPA-mediated metastatic dissemination of 
breast cancers. Using both genetic and pharmacological 
approaches in vitro and in vivo we demonstrate that the 
pro-invasive activity of LPA in TNBC cells depends on 
the LPA
1
/Pi3K/ZEB1/miR-21 activation cascade. These 
¿QGLQJVLGHQWLI\/3$
1
 as a potential therapeutic target for 
patients with triple negative breast cancers.
RESULTS
LPAR1 expression correlates with ZEB1 in basal 
breast cancers
In order to identify the genes correlated with LPAR1, 
we screened nine publicly available breast tumor databases 
(GSE2109; GSE5460; GSE1456; GSE2034; GSE12276; 
GSE3494; GSE2603; GSE7390; GSE16391) comprising 
of a total of 1488 patient samples. We found ZEB1 to be 
the most correlated gene to LPAR1 (Table 1). To further 
explore whether the correlation between LPAR1 and ZEB1 
ZDVVSHFL¿FWRDSDUWLFXODUVXEW\SHRIEUHDVWFDQFHUZH
sub-grouped patient samples from 3 publicly available 
databases of primary breast tumor (GSE20685; GSE21653; 
GSE1456) into basal (n = 75) and non basal subtypes 
(n = 138) based on the ER, PR and HER2 receptor 
expression status. We found that the correlation between 
LPAR1 and ZEB1 was stronger in the basal subtype (R 
Spearma n = 0.59) of human primary breast tumors than 
the non-basal subtype (R Spearma n = 0.40) (Figures 
1a and 1b). We then extracted the LPAR1 and ZEB1 
expression data from 51 human breast cancer cell lines 
from the publically available database GSE12777, 
FODVVL¿HG LQWR EDVDO n = 24) and non basal subtypes 
(n = 27). We observed that 54.16% of the basal breast 
cancer cell lines expressed LPAR1 and 37.5% expressed 
ZEB1 above the overall means. In contrast, only 11.1% 
of the non basal breast cancer cell lines expressed LPAR1 
and none expressed ZEB1 above the corresponding 
overall means (Figures 1c and 1d). Scatter plot analysis 
(Figures 1e and 1f) for LPAR1 and ZEB1 correlation in 
the non basal and basal breast cancer cell lines highlights 
the fact that LPAR1 and ZEB1 expression correlates 
VLJQL¿FDQWO\ LQ WKH EDVDO EXW QRW LQ WKH QRQEDVDO
subtypes. We did not observe any positive correlation 
between LPAR2 and LPAR3 to ZEB1 in either subtype 
(Supplementary Figures 1a, 1b, 1c, 1d, 1e and 1f).
Functional blockade of LPA
1
 inhibits ZEB1 
expression in vitro and in vivo
We chose the human basal breast cancer cell lines 
MDA-MB-231, MDA-BO2 and Hs578T to analyze the 
role of LPA and LPA
1
 on ZEB1 expression in vitro and 
in vivo6WLPXODWLRQZLWK/3$FDXVHGVLJQL¿FDQWXSUHJXODWLRQ
of ZEB1 mRNA and protein levels in all three cell lines 
(Figures 2a). LPA receptor expression screening showed 
that LPA
1
 was predominantly expressed in all the three cell 
lines (Figure 2b). While LPA
2
 was also expressed in MDA-
MB-231 cells, all three cell lines had very low or undetectable 
levels of LPA
36
 (Figure 2b). To further validate the 
relationship between LPA
1
 and ZEB1 we used MDA-MB-231 
cells, as they co-express both LPA
1
 and LPA
2
. Blocking LPA
1
 
H[SUHVVLRQE\WUDQVIHFWLQJWKHVHFHOOVZLWKVL51$VSHFL¿FDOO\
directed against LPA
1
 (Supplementary Figure 2a) as well as 
by treatment with the pharmacological antagonist of LPA
1/3
, 
Ki16425 [15] inhibited the LPA-induced ZEB1 expression at 
both mRNA and protein levels (Figures 2c and 2d).
To assess the effect of antagonizing LPA
1
 on ZEB1 
expression in vivo, we used an animal model of pre-
established bone metastases caused by MDA-MB/B02.Luc 
cells. A short treatment period (daily administration for 5 
days) of Ki16425 from day 18 post-tumor cell injection 
(Figure 2f), had no effect on the extent of bone metastasis 
lesions detected by BLI (Figure 2g) and X-ray (Figure 2h) 
analyses. Immunohistochemistry analyses performed on the 
bone sections from tumor bearing hind limbs revealed no 
VLJQL¿FDQWGLIIHUHQFHRI.LVWDLQLQJLQ.LWUHDWHG
group compared to vehicle-treated group, indicating that 
the agent had no effect on cell proliferation. In contrast, the 
signal intensity of ZEB1 staining in the Ki16425 group was 
markedly lower than that of the vehicle group (Figure 2i), 
suggesting that inhibition of LPA
1
 activity in vivo inhibits 
ZEB1 expression at the site of bone metastases.
To identify the signaling pathway regulating the 
LPA/LPA
1
-induced ZEB1 expression, we treated MDA-
MB-231 cells with the Pi3K inhibitor wortmannin 
ȝ0RUWKH0(.LQKLELWRU3'ȝ02QO\
wortmannin treatment was able to inhibit LPA-induced up-
regulation of ZEB1 in these cells, suggesting that the LPA/
LPA
1
-induced ZEB1 expression was mediated through a 
Pi3K-dependent signaling pathway (Figure 2e).
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Table 1: Highest positively correlated genes (Top50) to LPAR1 in human primary breast tumors
Rank Gene symbol Coeff. of correlation Gene name
1 ZEB1 0,62178 =LQF¿QJHU(%R[ELQGLQJKRPHRER[
2 TCF4 0,58822 Transcription factor 4
3 HTRA1 0,58344 HtrA serine peptidase 1
4 RECK 0,56756 reversion-inducing-cysteine-rich protein with kazal motifs
5 ZCCHC24 0,55633 ]LQF¿QJHU&&+&GRPDLQFRQWDLQLQJ
6 SPARCL1 0,55544 SPARC-like protein 1
7 SPON1 0,54889 Spondin 1
8 DCN 0,54867 Decorin
9 GLT8D2 0,54800 Glycosyltransferase 8 Domain Containing 2
10 ECM2 0,54656 Extracellular Matrix Protein 2
11 PDGFRL 0,54478 Platelet-Derived Growth Factor Receptor-Like
12 LRRC17 0,54233 Leucine rich repeat containing 17
13 EFEMP2 0,54211 (*)FRQWDLQLQJ¿EXOLQOLNHH[WUDFHOOXODUPDWUL[SURWHLQ
14 FBLN1 0,53767 Fibulin1
15 ZFPM2 0,53689 =LQF¿QJHUSURWHLQ)2*IDPLO\PHPEHU
16 OLFML1 0,52800 Olfactomedin-like 1
17 CFH 0,52522 Complement factor H
18 BICC1 0,52456 Bicaudal C homolog 1
19 KANK2 0,52433 KN motif and ankyrin repeat domains 2
20 PDGFC 0,52278 Platelet derived growth factor C
21 PLSCR4 0,52189 Phospholipid scramblase 4
22 FBN1 0,52133 Fibrillin 1
23 MMP2 0,52089 Matrix metallopeptidase 2
24 NDN 0,52089 Necdin, melanoma antigen (MAGE) family member
25 EDNRA 0,51422 Endothelin receptor type A
26 LDB2 0,51378 LIM domain binding 2
27 GAS7 0,51322 *URZWKDUUHVWVSHFL¿F
28 ZNF423 0,51122 =LQF¿QJHUSURWHLQ
29 FSTL1 0,50956 Follistatin-like 1
30 CRISPLD2 0,50467 Cysteine-rich secretory protein LCCL domain containing 2
31 CTSK 0,50222 Cathepsin K
32 PCOLCE 0,50022 Procollagen C-endopeptidase enhancer
33 OMD 0,49878 Osteomodulin
34 SERPINF1 0,49444 Serpin peptidase inhibitor, clade F member 1
35 CDH11 0,49089 Cadherin 11, type 2, OB-cadherin (osteoblast)
36 ASPN 0,48944 Asporin
(Continued )
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LPA up regulates microRNA miR-21 through a 
LPA
1
dependent mechanism
In order to further identify the genes involved in the 
metastatic properties of LPA, we carried out a microarray 
SUR¿OLQJRIPL51$VLQ0'$0%FHOOV LQUHVSRQVH
to LPA stimulation (GSE64100). Micro-RNA miR-21 was 
found to be one of the most up-regulated miRNAs in these 
cells following LPA stimulation (Figure 3a). MicroRNA 
miR-21 is known to act as an oncomiR, promoting 
metastasis in a large number of cancer types [16, 17]. 
8VLQJWKH7DT0DQ5743&5V\VWHPZHFRQ¿UPHGWKHXS
regulation of miR-21 by LPA in MDA-MB-231 cells and 
determined that LPA induced a dose-dependent increase 
in miR-21 expression by three to four folds after 45 min 
H[SRVXUH(& ȝ0WKDWLVVXVWDLQHGIRUDWOHDVWK
(Figure 3b). In subsequent in vitro studies, cells were treated 
ZLWK /3$  ȝ0 IRU PLQ WR UHÀHFW HDUO\ H[SRVXUH
times of cells to LPA during the metastatic process. First, 
we observed that up regulation of miR-21 by LPA was a 
common feature between all the three basal human breast 
cancer cell lines, MDA-MB-231, MDA-B02 and Hs578T, 
(Figure 3c). As LPA
1
 was the predominant LPA receptor 
expressed by these cells, we silenced LPA
1
 expression by 
transient transfection of siLPA
1
)LUVWZHFRQ¿UPHGWKDW
silencing LPA
1
 had no impact on the expression of the 
other LPA receptors (Supplementary Figure 2a, 2b, 2c). 
Intriguingly silencing LPA
1
 completely abolished LPA-
induced miR-21 expression in all three cell lines (Figure 3d). 
Moreover, the treatment of the cells with Ki16425 inhibited 
LPA-induced miR-21 expression (Figure 3e). LPA is a 
constituent of the serum [18] that mediates tumor cells 
proliferation and invasion [8]. We found that Ki16425 
treatment also inhibited miR-21 expression induced by 
serum in MDA-MB-231 cells (Figure 3f). To identify the 
signaling pathways regulating the LPAR1/miR-21 axis we 
used the same strategy as previously by treating the MDA-
MB-231 cells with wortmannin or PD98059. Again, only 
wortmannin was able to inhibit LPA-induced miR-21 
expression (Figure 3g), suggesting that LPA up-regulated 
miR-21 through an LPA
1
/PI3K-dependent mechanism.
LPA-induced ZEB1 expression up regulates 
miR-21 in human primary breast tumors
As LPA mediated up regulation of both ZEB1 and 
miR-21 through a common LPA
1
/PI3K axis, and because the 
strong correlation between ZEB1 and LPAR1, we examined 
the correlation between LPAR1, ZEB1 and miR-21 in 
human primary breast tumors. LPAR1/miR-21, ZEB1/miR-
21 and LPAR1/ZEB1 pairwise correlations were determined 
using data from in three publically available human breast 
cancer databases containing both mRNA and microRNA 
data (GSE5460; GSE16391; GSE12276). We found that 
ZEB1/miR-21, LPAR1/ZEB1 and LPAR1/miR-21 correlated 
VLJQL¿FDQWO\LQDOOWKUHHGDWDEDVHV)LJXUHVD±F
To examine the direct link between LPA, ZEB1 
and miR-21 expression, MDA-MB-231 cells were 
transfected with synthetic siRNAs against ZEB1 
(Figure 4d). Silencing ZEB1 caused complete inhibition of 
Rank Gene symbol Coeff. of correlation Gene name
37 NAV3 0,48933 Neuron navigator 3
38 PMP22 0,48733 Peripheral myelin protein 22
39 TGFB3 0,48611 Transforming growth factor, beta 3
40 COPZ2 0,48489 Coatomer protein complex, subunit zeta 2
41 LAMA2 0,47978 Laminin, alpha 2
42 FERMT2 0,47378 Fermitin family member 2
43 PALLD 0,47233 Palladin, cytoskeletal associated protein
44 EHD2 0,47211 EH-domain containing 2
45 LUM 0,46922 Lumican
46 OLFML3 0,46856 Olfactomedin-like 3
47 PDGFRB 0,46711 Platelet-derived growth factor receptor, beta polypeptide
48 NID1 0,46444 Nidogen 1
49 THBS2 0,46444 Thrombospondin 2
50 ANGPTL2 0,46411 Angiopoietin-like 2
The table shows the top 50 highest positively correlated genes to LPAR1 (204036_at) across 9 publically available breast tumor 
databases (GSE2109; GSE5460; GSE1456; GSE2034; GSE12276; GSE3494; GSE2603; GSE7390; GSE16391) comprising a 
total of 1488 samples. The list of correlated genes to LPAR1 was extracted using R2 genomics analysis and visualization platform.
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LPA-induced miR-21 expression (Figure 4e) resulting in 
DVLJQL¿FDQWLQFUHDVHLQWKHP51$OHYHOVRINQRZQPL5
21 target genes PTEN, PDCD4 and SPRY2 (Figure 4f), 
suggesting that LPA might functionally impact on miR-21 
activity through ZEB1.
LPA is known for activating different transcription 
factors, including cFos and STAT3, in different cell lines 
>@DQGWKLVZDVFRQ¿UPHGLQ0'$0%DQG
MDA-B02 cells (Figure 5a and 5b). Because these factors 
also are regulators of miR-21 expression we evaluated 
whether cFos and STAT3 could mediate LPA-induced 
miR-21 expression. Silencing cFOS or STAT3 using 
VSHFL¿F VL51$V LQ 0'$0% FHOOV )LJXUHV F
and 5d) did not alter LPA-induced miR-21 expression 
(Figures 5e and 5f).
Altogether these results indicate that LPA induces 
miR-21 expression through an LPA
1
/PI3K/ZEB1-
dependent pathway.
Figure 1: High correlation between LPAR1 and ZEB1 in basal breast cancer subtype. Scatter plots for LPAR1 and ZEB1 
gene correlation were constructed using data combined from three publically available databases (GSE20685, GSE21653, and GSE1456) 
of human primary breast tumors of a. non basal subtype (n = 138; r spearma n = 0.40) and b. basal subtype (n = 75, r spearma n = 0.59). 
c. LPAR1 and d) ZEB1 expression data from 51 breast cancer cell was extracted using BIOGPS online tool from GSE12777 data set, sub-
FODVVL¿HGLQWRQRQEDVDOn = 27) and basal (n = 24) subtypes. The scatter plots are also shown for the correlation between LPAR1 and ZEB1 
for both the e) non basal (n UVSHDUPDQ íDQGf. basal (n = 24; r spearma n = 0.43) subtypes of human breast cancer cell lines.
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LPA
1
 and ZEB1 mediate LPA-induced basal 
breast cancer migration and invasion in a miR-
21-dependent manner
To examine the functional impact of the LPA
1
/
ZEB1/miR-21 pathway on the metastatic activity of 
LPA on basal breast cancer cells we carried out wound 
healing migration assays and matrigel invasion assays. 
Transfecting MDA-MB-231 and Hs578T cells with 
antimiR-21, SiLPA1 or SiZEB1 alone impaired LPA-
induced cell migration (Figure 6a, 6c, 6e) and invasion 
(Figure 6b, 6d, 6f) as compared to the cells transfected 
with the Negative Control (antimiR control) or BlockiT 
(SiRNA control). Remarkably, in all cases, impaired 
motility and invasion was rescued when cells were co-
transfected with a mirVana miR-21 mimic. This suggested 
that the role of LPA in these metastatic processes was 
mediated by miR-21 through the expression of ZEB1, 
down-stream activation of LPA
1
.
Basal breast cancer cell bone colonization 
depends on miR-21 downstream ZEB1 activation
Micrometastasis formation is a well-recognized poor 
prognostic marker in breast cancers [21]. Patients with tripe 
negative metastasize to bone and with a higher incidence to 
Figure 2: LPA
1
 mediates LPA-induced expression of ZEB1 in vitro and in vivo. ZEB1 mRNA and protein levels were 
TXDQWL¿HG LQEDVDOEUHDVWFDQFHUFHOO OLQHVa. MDA-231 (MDA-MB-231), MDA-BO2 and Hs578T basal human breast cancer cells on 
LPA (10 µM) stimulation. **, p < 0.01 vs correponding unstimulated cells using unpaired two-tailed student t-Test. b. Screening of LPA 
UHFHSWRUH[SUHVVLRQVLQ0'$0%0'$%2DQG+V7FHOOV=(%P51$DQGSURWHLQOHYHOVZHUHTXDQWL¿HGRQ0'$0%
cells c. transfected with SiRNA against LPA
1
 and d. on treatment with Ki16425 (10 µM) in presence of LPA (10 µM) **, p < 0.01 vs 
BlockIT-transfected cells ; ***, p < 0.001 vs LPA stimulated MDA-MB-231 cells using unpaired two-tailed student t-Test. e. ZEB1 levels 
ZHUHTXDQWL¿HGE\5HDOWLPH573&5RQWUHDWPHQWZLWK3,.LQKLELWRUZRUWPDQQLQRU0(.LQKLELWRU3'LQSUHVHQFHRI/3$ 
(10 µM) ZEB1 protein levels were also validated by Western blot. #, p < 0.05; ##, p < 0.01 vs unstimulated untreated 231 cells using one-
way ANOVA with a Bonferroni post-test. f. MDA-BO2.luc cells were injected intravenously in Balb/c nude mice. The hind limbs were 
collected after 5 days of Ki16425 (25 mg/kg) treatment since the osteolytic lesions were observed by BLI (Day18). Images of g. BLI and 
h. X-Ray are shown from the vehicle treated and the Ki16425 treated group. i. Images of immunohistochemistry performed for Ki67 and 
ZEB1 are shown. The staining was done on 5 µM FFPE sections of the hind limbs collected from vehicle treated and Ki16425 treated 
groups. All values for results shown in panels A, B, C, D, I were the mean ± SD of 3 experiments.
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lungs and brain [12]. To examine the role of miR-21 during 
the early phase of breast cancer cell metastasis we used our 
mouse model of tumor cell colonization to bone (TCB) in 
which MDA-BO2.luc cells transfected with AntimiR-21 or 
Negative control were injected intravenously BALB/c nude 
mice. Cancer cells that colonized the bone marrow cavity 
were collected seven days post injection and expanded 
in vitro for two weeks in the presence of puromycin that 
kills non-tumoral cells. Counting of tumor clones revealed 
that silencing miR-21 decreased TCB clone number by 
70% compared to control (p < 0.001). This result indicated 
that miR-21 drives basal breast cancer cell metastasis to 
bone (Figure 7a).
We next addressed the functional relationship 
between miR-21 and ZEB1 in vivo using the TCB 
mouse model. Mice were injected with MDA-BO2.
luc cells transfected with BlockiT (control SiRNA) or 
SiZEB1+BlockiT or SiZEB1+miR-21 mimic. Silencing 
=(% VLJQL¿FDQWO\ LPSDLUHG WKH 7&% DV MXGJHG E\ D
VLJQL¿FDQWO\GHFUHDVHE\p < 0.001) in the number of 
TCB clones compared to the control group. Interestingly, 
the inhibition in the TCB induced by silencing ZEB1 was 
abolished when the cells were previously co-transfected 
with miR-21 mimic. The number of TCB clones in the 
groups of mice injected with breast cancer cells transfected 
ZLWK 6L=(%PL5 PLPLF ZDV QRW VLJQL¿FDQWO\
Figure 3: LPA
1
 regulates LPA-induced miR-21 expression. a. Heat map was constructed for the upregulated miRNAs in MDA-
MB-231 cells on LPA stimulation (1 µM) b.PL5H[SUHVVLRQZDVTXDQWL¿HGXVLQJ0'$0%RQVWLPXODWLRQZLWKDQLQFUHDVLQJGRVH
of LPA (0.0001 µM to 50 µM) at 45min and 24 h respectively. . #, p < 0.05; ##, p < 0.01; ###, p < 0.001 vs Unstimulated 231 cells using one-
way ANOVA with a Bonferroni post-test. c. qRT-PCR analysis of miR-21 was performed on MDA-MB-231, MDA-BO2 and Hs578T on 
LPA stimulation (10 µM) ***, p < 0.001 vs unstimulated 231/BO2 cells using unpaired two-tailed student t-Test. d. Relative expression of 
PL5ZDVTXDQWL¿HGE\5HDOWLPH573&5E\SHUIRUPLQJWUDQVLHQWWUDQVIHFWLRQZLWK6L51$DJDLQVW/3$
1
, and BlockiT (control SiRNA) 
on MDA-MB-231, MDA-BO2 and Hs578T cells on LPA (10 µM) stimulation. **, p < 0.01 vs BlockiT transfected unstimulated 231/BO2/
Hs578T cells using unpaired two-tailed student t-Test. e.PL5UHODWLYHH[SUHVVLRQZDVTXDQWL¿HGLQ0'$%2FHOOVRQWUHDWPHQWZLWK
different doses (0.1 µM, 1 µM, 10 µM) of Ki16425 (LPA
1
 and LPA
3
 antagonist) in presence of LPA (10 µM) or f. in presence of serum. 
##, p < 0.01 vs Unstimulated BO2 cells using one-way ANOVA with a Bonferroni post-test; **, p < 0.01 vs unstimulated BO2 cells using 
unpaired two-tailed student t-Test. g.PL5OHYHOVZHUHTXDQWL¿HGE\5HDOWLPH573&5RQWUHDWPHQWZLWK3,.LQKLELWRUZRUWPDQQLQ
or MEK1/2 inhibitor (PD98059) in presence of LPA (10 µM) ##, p < 0.01 vs unstimulated untreated 231 cells using one-way ANOVA with 
a Bonferroni post-test. All values for results shown in panels B, C, D, E, F, G were the mean ± SD of 3 experiments.
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different to those obtained with cells transfected with 
BlockiT (Figure 7b). These results indicated that ZEB1 
regulates the TCB in a miR-21-dependent manner.
Finally we analyzed whether LPAR1 levels might 
have an impact on metastasis recurrence in basal breast 
cancers. Among several publically available databases 
with representative breast cancer patient populations sub-
FODVVL¿HGLQEDVDODQGQRQEDVDOWXPRUVZHXVHGWKH*(2
database GSE2603 that additionally provided clinical 
recording of different tissue metastases. As opposed to 
records of recurrence data to the lungs the number of bone 
metastasis events in these populations was too low for 
developing a comprehensive statistical analysis. However, 
using the median value of LPAR1 level as cut-off in each 
population, the predictive value for lung metastasis-
free survival of LPAR1OHYHOVZDVVLJQL¿FDQWO\GLIIHUHQW
comparing the group of patients with basal tumors 
versus those with non-basal tumors. Patients with basal 
tumors but not with non-basal tumors expressing high 
LPAR1 levels had a worse lung-metastasis-free survival 
(P < 0.05) (Figure 8a). These results suggested that LPAR1 
level could be considered as a new prognostic factor for 
patients with basal breast cancers.
DISCUSSION
LPA exhibits complex mode of actions, due to multi-
gene programs activated downstream of multiple LPA 
Figure 4: ZEB1 controls LPA-induced miR-21 expression through LPA
1
 activity. Scatter plots of miR-21 expression and 
LPAR1 expression; miR-21 expression and ZEB1 expression; LPAR1 expression and ZEB1 expression were constructed with the Log2 
tranformed values extracted from three publically available databases a. GSE5460, b. GSE16391, c. GSE12276 using R2 genomics 
analysis and visualization platform. Analysis of correlation and computation of linear regression of the data were performed using Prism 
v5.0b (GraphPad Software, Inc.). pZHUHFRQVLGHUHGVLJQL¿FDQW0'$0%FHOOVZHUHWUDQVLHQWO\WUDQVIHFWHGZLWKV\QWKHWLF
SiRNAs against ZEB1 (SiZEB1) and the control SiRNA (BlockiT) in presence of LPA (10 µM) d.=(%OHYHOVZHUHTXDQWL¿HGWRYDOLGDWH
WKHHI¿FDF\RIWKH6L=(%p < 0.001 vs BlockIT transfected LPA stimulated cells using unpaired two-tailed student t-Test. e. miR-21 
OHYHOVZHUHTXDQWL¿HGE\WDTPDQUHDOWLPH573&5p < 0.01 vs BlockIT transfected unstimulated 231 cells using unpaired two-tailed 
student t-Test. f.7KHP51$OHYHOVRIWKHWDUJHWJHQHVRIPL537(13'&'635<ZHUHTXDQWL¿HGLQWKH6L=(%DQGWKH%ORFNL7
transfected MDA-MB-231 cells only on LPA (10 µM) stimulation. **, p < 0.01 vs BlockIT transfected LPA stimulated 231 cells using 
unpaired two-tailed student t-Test. All values for results shown in panels D, E, F were the mean ± SD of 3 experiments.
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receptor subtypes that are frequently co-expressed in cells 
and tissues and having potential synergistic and opposite 
functions [1]. Integrating genetic and pharmacological 
approaches in vitro and in vivo we demonstrate that the pro-
invasive activity of LPA on triple negative breast cancer cells 
depends on an LPA
1
/PI3K/ZEB1/miR-21 activation cascade.
Overexpression of other LPA receptors, LPA
2
 and 
LPA
3
, has been previously linked to the progression of breast 
cancers [4]. However, activated genes driving the oncogenic 
SRWHQWLDORIWKHVHUHFHSWRUVKDYHQRWEHHQGH¿QHG$VRSSRVHG
to LPAR1ZHGLGQRWREVHUYHVLJQL¿FDQWFRUUHODWLRQVEHWZHHQ
ZEB1 and LPAR2 or LPAR3 in publicly available breast cancer 
cell line databases. The strong correlation between ZEB1 and 
LPAR1 was most prominent in primary tumors of patients 
with basal breast cancers. Moreover, in addition to a higher 
prevalence of LPA
1
 expression in basal than in non-basal 
EUHDVWFDQFHUFHOOOLQHVWKHUHZDVDVLJQL¿FDQWFRUUHODWLRQ
between ZEB1 and LPAR1 in cell line of basal subtypes but 
not of non-basal subtype. This suggests that controlling ZEB1 
expression through LPA
1
 activation might have a functional 
impact on basal breast cancer behaviors. ZEB1 is a known 
driver of the epithelial-to-mesenchymal transition (EMT), 
conferring metastasis and drug resistance properties to 
epithelial cells and contributing to the poor clinical outcomes 
[22]. Therefore, mediators of ZEB1 might represent potential 
therapeutic targets for metastasis suppression. In vitro, 
inhibition of LPA
1
 expression using SiLPA
1
, or blocking its 
activity with the LPA
1/3
 DQWDJRQLVW .L VLJQL¿FDQWO\
inhibited LPA-induced expression of ZEB1. Functional 
involvement of LPA
1
 in ZEB1 expression in vivo was 
supported by the effect of a short treatment with Ki16425 
(5 days) of animals with pre-established skeletal metastases 
that markedly reduced ZEB1 expression in the tumor 
metastasis.
LPA
1
 is known to be responsible for LPA-induced cell 
mobility in both neoplastic and non-neoplastic cells [23]. 
+HUHZHGHPRQVWUDWHWKDWVSHFL¿FVLOHQFLQJRI/3$
1
 and 
ZEB1 inhibited the LPA-induced migration and invasion 
Figure 5: LPA-induced miR-21 expression is independent of STAT3 and cFOS. a. cFOS, b. STAT3 mRNA and protein levels 
ZHUHTXDQWL¿HGLQ0'$0%DQG0'$%2FHOOVE\5743&5RQ/3$0) stimulation. MDA-MB-231 cells were transiently 
transfected with synthetic SiRNAs against cFOS (SicFOS), STAT3 (SiSTAT3) and the control SiRNA (BlockiT) in presence of LPA (10 
µM) and the c. cFOS and d.67$7OHYHOVZHUHTXDQWL¿HGWRYDOLGDWHWKHHI¿FDF\RIWKH6L51$¶Ve, f.PL5OHYHOVZHUHTXDQWL¿HGLQ
these SicFOS and SiSTAT3 transfected cells by taqman real time RT-PCR. *, p < 0.05, **, p < 0.01 ***, p < 0.001 using unpaired two-tailed 
student t-Test. All values were the mean ± SD of 3 independent experiments.
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of basal breast cancer cell lines, supporting that ZEB1 is 
a downstream activated transcription factor of the LPA/
LPA
1
 axis stimulating cell motility. Silencing ZEB1 leads 
to inhibition of bladder cancer cell migration and invasion 
[24]. In bladder cancer cells ZEB1 regulates vimentin, 
MMP2 and cytokeratins [24]. Interestingly, MMP2 gene 
expression correlates to LPAR1 in human primary breast 
WXPRUVKLWLQ7DEOH0RUHRYHUZHUHFHQWO\LGHQWL¿HG
a set of 74 early genes including VIM (the gene encoding 
vimentin) that are up-regulated in a LPA
1
-dependent manner 
in breast and prostate cancer cells stimulated with LPA [25]
(GEO Series accession number GSE56265). In addition, 
LPA-induced ZEB1 expression in basal breast cancer 
cells was mediated through a PI3K-dependent but not of a 
MEK1-dependent signaling pathway. In bladder cancer cells 
LY294002, a PI3K inhibitor, inhibits phosphorylation of 
Figure 6: LPA-induced cell migration and invasion depend on miR-21 activity down-stream activation of LPA
1
 and 
ZEB1. Wound healing assay was performed on MDA-MB-231 (Ů) and Hs578T (Ů)cells transfected with a. negative control antimiR, 
antimiR-21+negative control antimiR and antimiR-21+miR-21 mimic; c. BlockiT, SiLPA
1
+BlockiT and SILPA
1
+miR-21 mimic and 
e. BlockiT, SiZEB1+BlockiT and SIZEB1+miR-21 mimic on LPA (1 µM) stimulation for which the representative images and the 
TXDQWL¿FDWLRQRIWKHDUHDRIFHOOPLJUDWHGVKRZQDUHDWKIRU0'$0%DQGKIRU+V7DIWHUZRXQGLQJ7KHEDUUHSUHVHQWV
200 µM. All values were the mean ± SD of 3 experiments. **, p < 0.01 vs unstimilated Neg.Ctrl AntimiR or BlockiT transfected MDA-
MB-231 or Hs578T cells using one-way ANOVA with a Bonferroni post-test. For matrigel invasion assay 7.5 × 104 MDA-MB-231 cells 
were transfected with b. negative control antimiR, antimiR-21+negative control antimiR and antimiR-21+miR-21 mimic; d. BlockiT, 
SiLPA
1
+BlockiT and SILPA
1
+miR-21 mimic; f. BlockiT, SiZEB1+BlockiT and SiZEB1+miR-21 mimic and were seeded on matrigel 
coated transwells and incubated for 24 h with LPA (1 µM)DVFKHPRDWWUDFWDQW&HOOZHUH¿[HGDQGVWDLQHGZLWKPHWKDQRODQGFU\VWDOYLROHW
DQGFRXQWHGDQGSKRWRJUDSKHGIURPUDQGRP¿HOGVIURPRQHLQVHUW7KHUHSUHVHQWDWLYHLPDJHVDUHVKRZQ7KHEDUUHSUHVHQWV0
All values were the mean ± SD of 3 experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001 vs Neg.Ctrl AntimiR or BlockiT using one-way 
ANOVA with a Bonferroni pos t-test.
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$.7DQG*6.ȕDQG=(%H[SUHVVLRQGXHWRLQKLELWLRQRI
ȕFDWHQLQWUDQVFULSWLRQIDFWRU7&)FRPSOH[ELQGLQJDQG
transcriptional activity on ZEB1 promoter [26]. Intriguingly, 
our analysis of the nine publically available databases of 
human primary breast tumors revealed that after ZEB1, 
7&)KDGWKHKLJKHVW6SHDUPDQFRUUHODWLRQFRHI¿FLHQWWR
LPAR1 (hit 2 in Table 1). Altogether, these data suggest that 
activation of ZEB1 through the PI3K/AKT pathway might 
represent a general mechanism in LPA-induced cancer 
cell invasion and metastasis. In addition, phosphorylation 
RI*6.ȕPLJKWSOD\DSLYRWDOUROHLQFRRUGLQDWLQJ/3$
signals dependent on Pi3K/AKT activation that mediate 
ȕFDWHQLQ7&)LQGXFHG=(%H[SUHVVLRQ
Breast cancer dissemination involves multi-gene 
programs coordinated by transcription factors. MicroRNAs 
are post-transcriptional gene expression regulators that are 
also involved in breast cancer metastasis [2729]. LPA 
triggers a series of 74 early genes directly through the 
activation of LPA
1
 in breast and prostate cancer cells [25]. 
Here we showed that exposure to LPA for only 45 min 
up-regulates 36 microRNAs in MDA-MB-231 cells. We 
focused our attention on miR-21 because it is known to 
act as an oncomiR. High miR-21 expression is reported to 
promote invasion and proliferation of multiple cancer cell 
types, including breast [30, 31] [3235]. Using a mouse 
PRGHOZHFRQ¿UPHGWKDWPL5FRQWUROVEUHDVWFDQFHUFHOO
migration and invasion in vitro, and metastasis using tumor 
cell colonization of bone as an endpoint in vivo. Moreover, 
it has been determined that ZEB1 is an upstream regulator 
of miR-21 [36]. In this study we demonstrated that in human 
EUHDVW WXPRUV WKHUHZDVDVLJQL¿FDQWSRVLWLYHFRUUHODWLRQ
between LPAR1, ZEB1 and miR-21 and that in basal breast 
Figure 7: ZEB1 controls miR-21-dependent tumor cell bone colonization. Tumor bone colonization experiment was performed 
using MDA-BO2.Luc cells transfected with a. Negative control antimiR or AntimiR-21; b. BlockiT or SiZEB1+BlockiT or SiZEB1+miR-21 
mimic. The schema of the experiments are shown in the respective panels. The tranfected cells were injected intravenously through the tail 
vein. The picture of each well shown represents the bone marrow cells collected from one mice and cultured for 2 weeks in the presence 
RISXURP\FLQȝJPO&RORQLHVFRUUHVSRQGLQJWRWXPRUFHOOVWKDWFRORQL]HGWRERQH7%&ZHUH¿[HGDQGVWDLQHGZLWKPHWKDQRO
crystal violet (v/v) (scale bar: 1 cm). TBC colonies were counted. Results are expressed as mean of TBC (± S.E.M). ***, p < 0.001 versus 
mice injected with Neg.Ctrl AntimiR or Blockit transfected cells using two-tailed Mann Whitney test.
Oncotarget20615www.impactjournals.com/oncotarget
cancer cell lines ZEB1 regulates LPA-induced miR-21 
expression through an LPA
1
/PI3K dependent mechanism.
We showed previously that blocking LPA
1
 activity 
inhibits early stage of breast cancer cell metastasis to 
lungs and bone, independently of cell proliferation and 
angiogenesis but through inhibition of cell motility and 
invasion [9]. Inhibiting in vitro miR-21 activity with 
the MirVana miR-21 inhibitor, or silencing LPA
1
 or 
ZEB1 independently resulted in a complete block of 
LPA-induced cell migration and invasion. In all cases, 
basal breast cancer cell functions were rescued by co-
transfecting the cells with a miR-21 mimic molecule, 
indicating that LPA-induced basal breast cancer cell 
migration and invasion was regulated in a miR-21-
dependent manner, down-stream of LPA
1
 and ZEB1 
activations. This pathway might have a functional impact 
on the establishment of metastases as shown by the 
inhibition of micromedullar metastasis formation with 
silenced expression of ZEB1 that was rescued following 
introduction of mirVana miR-21 mimic.
Figure 8: LPAR1 level is a predictive factor for lung metastasis recurrence in basal breast cancers. Kaplan-Meier curves 
depicting 5 year lung metastases-free survival of a. 57 non basal breast cancer patients and b. 25 patients with basal breast cancer in primary 
breast tumor database GSE2603. Patients were divided into 2 groups based on the median of expression status of LPAR1. In the non basal 
breast tumor samples p < 0.039 versus LPAR1 high group and in the basal breast tumor samples p < 0.043 versus LPAR1 low group using 
Gehan-Breslow-Wilcoxon test. c. Schematic diagram representing the mechanism of LPA-induced early steps of metastasis formation. 
Acting on LPA
1
 receptor LPA activates PI3K/AKT inducing ZEB1 expression and down-stream activation of miR-21 that by inhibiting the 
expression of anti-metastatic genes (PTEN, PDCD4, SPRY2) induces cell migration, invasion and metastasis dissemination.
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%HVLGH D VWURQJ VLJQL¿FDQW FRUUHODWLRQ EHWZHHQ
high levels of LPAR1 mRNA and the lymph node 
status from an unselected breast cancer population, 
we previously found that LPAR1 levels did not predict 
metastasis recurrence [9]. Recent studies reported that 
JURZWKRI71%&FHOOVUHOLHVXSRQWKHSURLQÀDPPDWRU\
cytokines IL-6 and IL-8, whose secretion is regulated by 
WKH/3$1)ț%VLJQDOLQJFDVFDGH>@/3$
1
 is a well-
known inducer of IL-6 and IL-8 secretions in ovarian 
and breast cancer cells [38, 39]. Here, based on the sub-
FODVVL¿FDWLRQ RI KXPDQ EUHDVW WXPRUV IURP SXEOLFDOO\
DYDLODEOHGDWDEDVHVZHIRXQGIRUWKH¿UVW WLPHWKDWDV
opposed to non-basal breast cancer patients, expression 
levels of LPAR1 predicted lung metastasis-free survival 
in TNBC patients.
Overall our results demonstrate functional 
relationships between ZEB1 and miR-21 driving LPA-
dependent metastasis through LPA
1
 in basal breast cancers 
)LJXUHF2XU¿QGLQJVPD\KDYHDPDMRU LPSDFWE\
identifying a potential target for development of new 
adjuvant therapies of triple-negative breast cancer patients 
to prevent metastatic recurrences.
MATERIALS AND METHODS
Cell culture and reagents
Human breast cancer cell lines MDA-MB-231 and 
Hs578T were obtained and cultured as recommended by 
American Type Culture Collection (ATCC; Gaithersburg, 
MD, USA). Characterization of MDA-MB-231/B02 
(MDA-MB/B02) and MDA-BO2.Luc breast cancer 
cells and culture conditions were described previously 
[40] . Lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-
glycero-3-phosphate; 18:1) was obtained from Avanti 
Polar Lipids Inc, Alabama, USA. Ki16425 (LPA
1
/LPA
3
 
antagonist) was obtained from Cayman chemicals, 
Michigan, USA. Wortmannin (PI3K inhibitor) and 
PD98059 (MEK1 inhibitor) were purchased from 
TOCRIS, R&D systems.
Transfection
MDA-MB-231, MDA-BO2, MDA-BO2.Luc and 
Hs578T cells were transiently transfected with 50nM of 
mirVana miR-21 inhibitor (50 nM of mirVana miR-21
5p mimic, 50nM mirVana negative control, or 25nM of 
silencer select pre-designed SiRNA against LPAR1 , ZEB1, 
FOS or STAT3 (all from Ambion, Life technologies), 
Q0RI%/2&.L7$OH[DÀXRUDVQHJDWLYHFRQWURO
(Invitrogen, Life technologies) using Lipofectamine 
RNAiMAX Reagent (Invitrogen, Life technologies) 
following the manufacturers protocol. All siRNAs were 
composed of a pool of at least 2 differents siRNAs. The 
cells were used for in vitro or in vivo experiments 48 h post 
transfection.
RNA extraction, reverse transcription, and real 
time RT-PCR
Total RNAs including miRNA were extracted using 
miRNeasy kit (QIAGEN). TaqMan microRNA assays 
(Applied Biosystems, Life Technologies) were used to 
quantify miR-21 and RNU-48 levels according to the 
manufacturers recommendations. For gene expression 
analysis, cDNAs were synthesized using iScript cDNA 
Synthesis kit (Biorad) according to the manufacturers 
protocol and real-time quantitative was performed using 
the SYBR Green PCR kit (Life technologies) using 
VSHFL¿F3&5SULPHUV7DEOH(DFK3&5F\FOHFRQVLVWHG
of 10s of denaturation at 95°C, 15s of annealing at 67°C, 
and 10s of extension at 72°C.
miRNA microarray analysis
miRNA from cells were isolated using miRNeasy 
kit (QIAGEN). Total RNA (100 ng) was directly labeled 
with Cyanine-3-labeled and array hybridized for 20 h 
using miRNA complete labeling and hybridization kit 
(Agilent). The arrays were washed with gene expression 
wash buffer kit (Agilent) and read with High-resolution 
microarray scanner (Agilent). The data was extracted 
using Agilent feature extraction software (Agilent 
v11.5.1.1). The data were normalized by spike labelling. 
7KH PHGLDQ ÀXRUHVFHQW LQWHQVLWLHV ZHUH REWDLQHG DIWHU
subtracting background. To identify differential miRNA 
H[SUHVVLRQ EHWZHHQ VDPSOHV WKH PHGLDQ ÀXRUHVFHQW
intensities were normalized using the median expression 
values within the array and log2 values analyzed. Data 
was deposited on Gene expression omnibus, the accession 
code is GSE64100.
Western blot analysis
Cells lysates were loaded on a 7% Tris-acetate 
gel (Invitrogen) and subjected to electrophoresis under 
reducing conditions. After electrophoresis proteins 
were transferred onto Immobilon transfer membrane 
(MerckMillipore) and membranes were incubated with 
anti-ZEB1 (Abnova), anti-cFOS (Santa Cruz Biotech.), 
DQWL67$7 6DQWD &UX] %LRWHFK RU DQWLĮWXEXOLQ
(Sigma-Aldrich) antibodies. Detection of bound antibodies 
was performed using horseradish peroxide (HRP)-
conjugated donkey anti-rabbit and anti-mouse secondary 
antibodies (Amersham; 1/2000 dilution) and with 
enhanced chemiluminescence detection system (Perkin 
Elmer LAS Inc).
Wound healing and invasion assays
&RQÀXHQWFHOOFXOWXUHPRQROD\HUVZHUHFHOOVVFUDWFKHG
using a 10ul tip. Cells were washed with PBS to remove all 
the debris and incubated for 24 h (MDA-MB-231 cells) or 
48 h (Hs578T cells) with serum-free media supplemented 
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ZLWK/3$ȝ0,PDJHVZHUHWKHQFDSWXUHGXVLQJ1,.21
Coolpix 990 camera attached to a microscope and the area of 
cells migrated were tabulated using Morpho-expert software 
(Explora-nova). Cancer cell invasion across a Matrigel layer 
was performed as previously described [41]
Immunohistochemistry
7KH WXPRU EHDULQJ KLQG OLPEV ZHUH ¿[HG DQG
HPEHGGHG LQ SDUDI¿Q )LYH ȝP VHFWLRQV ZHUH GH
SDUDI¿QL]HG LQ PHWK\OF\FORKH[DQ K\GUDWHG WKURXJK D
graded series of ethanol, then immersed in a peroxidase 
blocking reagent (DakoCytomation) 5 min. Sections were 
incubated with normal goat serum for 30 min and incubated 
overnight at 4°C in humid chambers with primary antibody 
to Ki67 (dilution1:25) or to human ZEB1 (Abnova, 
PAB19268, dilution 1:300). The slides were incubated with 
biotinylated polyclonal rabbit anti-rat immunoglobulin 
(DakoCytomation) for 45 min. After washing, the slides 
were treated with peroxidase-conjugated streptavidin 
(DakoCytomation) for 45 min and developed by addition 
of a solution of 3, 39-diaminobenzidine tetrahydrochloride 
(DakoCytomation). Light counterstaining was performed 
with Mayers hematoxylin.
Animal experiments
Mice used in experimental procedures at the 
Université Claude Bernard Lyon1 (Lyon, France) were 
handled according to the rules of Décret N° 87848 du 
19/10/1987, Paris. The experimental protocol have been 
reviewed and approved by the Institutional Animal Care 
Table 2: Primer sequences
Name Sequence 5-3
ZEB1-F AGCAGTGAAAGAGAAGGGAATGC
ZEB1-R GGTCCTCTTCAGGTGCCTCAG
STAT3-F GCCAGAGAGCCAGGAGCA
STAT3-R ACACAGATAAACTTGGTCTTCAGGTATG
cFOS-F AGAATCCGAAGGGAAAGGAA
cFOS-R CTTCTCCTTCAGCAGGTTGG
LPA1-F AATCGAGAGGCACATTACGG
LPA1-R CTGTAGAGGGGTGCCATGTT
LPA2-F CGCTCAGCCTGGTCAAGACT
LPA2-R TTGCAGGACTCACAGCCTAAAC
LPA3-F GGAGGACACCCATGAAGCTA
LPA3-R GGAACCACCTTTTCACATGC
LPA4-F GCCTGCTACTCTGTCTCAAATTGG
LPA4-R GCAAGGCACAAGGTGATTGG
LPA5-F CTCGGTGGTGAGCGTGTACATG
LPA5-R GCGTAGCGGTCCACGTTGAT
LPA6-F AAATTGGACGTGCCTTTACG
LPA6-R TAACCCAAGCACAAACACCA
PDCD4-F TGGATTAACTGTGCCAACCA
PDCD4-R TCTCAAATGCCCTTTCATCC
SPRY2-F CCCCTCTGTCCAGATCCATA
SPRY2-R CCCAAATCTTCCTTGCTCAG
PTEN-F ACCAGGACCAGAGGAAACCT
PTEN-R GCTAGCCTCTGGATTTGACG
L32-F AGGAGCTGGAAGTGCTGC
L32-R CAGCTCTTTCCACGATGGC
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and Use Committee of the Université Claude Bernard 
Lyon-1 (Lyon, France). BALB/C nude mice purchased 
from Janvier Labs (Le Genest-Saint-Isle, France), 4 
weeks of age, were housed under barrier conditions in 
ODPLQDUÀRZLVRODWHGKRRGV$XWRFODYHGZDWHUDQGPRXVH
chow were provided ad libitum. Animals were carefully 
monitored for established signs of distress and discomfort 
DQGZHUHHXWKDQL]HGZKHQWKHVHZHUHFRQ¿UPHG
The institutional committee approving the 
experiments, including details regarding animal welfare 
are indicated in Supplementary Information 1. For the 
breast cancer cell colonization to bone (TCB) experiments, 
transfected MDA-B02.Luc cells were injected intravenously 
to BALB/c nude mice as previously described [42]. Seven-
GD\VSRVWLQMHFWLRQPLFHZHUHVDFUL¿FHGDQGKLQGOLPEV
were collected, dissected. Bones were minced and treated 
ZLWK ȝ/ RI JHQWOH FROODJHQDVHK\DOXURQLGDVH 6WHP
cell technologies) for 2 h at 37°C. The cell suspension was 
washed with phosphate buffer saline (PBS), plated in wells 
of a 6 well plate in complete culture media supplemented 
ZLWKSXURP\FLQȝJP/$IWHUZHHNVFORQHVRIWXPRU
FHOOVWKDWKDGFRORQL]HGERQH7&%ZHUH¿[HGDQGVWDLQHG
in 50% (v/v) methanol containing 0.05% (w/v) crystal violet 
and enumerated. For experiments on established osteolytic 
lesions, animals were injected with MDA-B02.Luc cells 
as previously described [40] and evidences of metastasis 
formation were determined by bioluminescence imaging 
(Nightowl, Berthold, Germany) and X-ray analyses (MX-
20; Faxitron X-ray corporation). Metastatic animals were 
then treated once daily for 5 days with 20 mg/kg Ki16425 
or the vehicle.
Microarray correlation analysis
To identify genes correlated with LPAR1 we 
FDOFXODWHGWKHFRHI¿FLHQWRIFRUUHODWLRQYDOXHVRILPAR1 
for all genes covered by the given microarray platform 
across 9 publically available breast tumor datasets 
(Gene Expression Omnibus (GEO) accession numbers: 
GSE2109, GSE5460, GSE1456, GSE2034, GSE12276, 
GSE3494, GSE2603, GSE7390, GSE16391) using R2 
genomics analysis and visualization platform. The list of 
JHQHVLQWKHGHVFHQGLQJRUGHURIFRHI¿FLHQWRIFRUUHODWLRQ
was generated after averaging the values across all 
9 databases. Publicly available gene expression data 
obtained from three independent studies comprising in 
total 138 luminal and 75 basal breast carcinoma samples 
were retrieved from the GEO (accession numbers: 
GSE20685, GSE21653, and GSE1456). Microarray 
data were generated on Affymetrix HG-U133Plus2.0 
or Affymetrix HGU133A arrays, respectively, and 
were simultaneously normalized by robust multi-array 
DYHUDJH50$XVLQJFXVWRPEUDLQDUUD\&')¿OHVY
ENTREZG) yielding one optimized probeset per gene as 
previously described [43]. LPAR1 and ZEB1 expression 
data from 51 breast cancer cell lines was extracted using 
BIOGPS online tool from GSE12777 data set. The 
FHOO OLQHVZHUHFODVVL¿HGDV OXPLQDO n = 27) and basal 
(n = 24) subtypes.
Statistical analysis
Analysis of correlation and computation of linear 
regression of the data were performed using GraphPad 
Prism v5.0c software. Differences between groups were 
determined by 1-way ANOVA followed by Bonferroni 
post-test. Single comparisons were carried out using non-
parametric Mann-Whitney test. Kaplan-Meier analysis for 
5 year lung metastases-free survival of 25 patients with 
basal (triple negative) breast cancer was performed using 
the GSE2603 dataset. Microarray transcriptomic data was 
normalized by robust multi-array average (RMA) using 
R-package yielding one optimized probeset per gene. 
Patients were divided in 2 groups based on the median 
of the expression of LPAR1. Gehan-Breslow-Wilcoxon 
test was performed to calculate the p value. p < 0.05 was 
FRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW
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